PAA.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:10):

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally...

Stats
Dzisiejszy wolumen	906 493
Średni wolumen	1.53M
Kapitalizacja rynkowa	92.97M
EPS	$0 ( 2024-02-25 )
Następna data zysków	( $0 ) 2024-07-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.00
ATR14	$0.00200 (0.95%)

Pharmaust Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharmaust Ltd Korelacja - Waluta/Towar

0.34
( neutral )

0.47
( neutral )

0.00
( neutral )

-0.52
( weak negative )

Pharmaust Ltd Finanse

Annual	2023
Przychody:	$2.82M
Zysk brutto:	$-929 535 (-32.92 %)
EPS:	$-0.0194

FY	2023
Przychody:	$2.82M
Zysk brutto:	$-929 535 (-32.92 %)
EPS:	$-0.0194

FY	2022
Przychody:	$3.38M
Zysk brutto:	$-223 517 (-6.61 %)
EPS:	$-0.00540

FY	2021
Przychody:	$2.14M
Zysk brutto:	$1.92M (89.47 %)
EPS:	$-0.00420

Financial Reports:

No articles found.

Pharmaust Ltd

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.